The accelerated approval of oncologic drugs: lessons from ponatinib.
Medical Oncology Service, National Cancer Institute, Bethesda, Maryland.
Vinay
V
Prasad
Medical Oncology Service, National Cancer Institute, Bethesda, Maryland.
Sham
S
Mailankody
D016907:Adverse Drug Reaction Reporting Systems; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D017277:Drug Approval; D033161:Government Regulation; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects* / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy; D011634:Public Health; D011724:Pyridazines / Q000009:adverse effects* / Q000627:therapeutic use; D013997:Time Factors; D014481:United States; D014486:United States Food and Drug Administration
D000970:Antineoplastic Agents; D007093:Imidazoles; D011724:Pyridazines; C545373:ponatinib